Veerendra Munugalavadla

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia”.

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1130

N/A

3.1DataRank · unranked

79 citations

James S. Blachly, Kerry A. Rogers, Seema A. Bhat, Mojgan Jianfar, Gerard Lozanski +11 more

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2547

N/A

1.3DataRank · unranked

29 citations

Courtney B. Betts, Lauren Maloney, Eric Nadler, Alain P. Algazi, Michael J. Guarino +10 more

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood(2025)10.1182/blood.2024024476

N/A

0.710DataRank · unranked

42 citations

Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn +22 more

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Cancer(2020)10.1002/cncr.33067

N/A

0.538DataRank · unranked

35 citations

Michael R. Harrison, Peter H. O’Donnell, Ajjai Alva, Noah M. Hahn, Leonard J. Appleman +17 more

Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia

British Journal of Haematology(2022)10.1111/bjh.18053

N/A

0DataRank · unranked

15 citations

Alec Griffith, Zixu Wang, Svitlana Tyekucheva, Vanessa Rai, Stacey M. Fernandes +5 more

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

Haematologica(2022)10.3324/haematol.2021.279560

N/A

0DataRank · unranked

4 citations

Sara K. Blick-Nitko, Andrea Baran, Derick R. Peterson, Hannah E. Whitehead, Raquel Izumi +7 more